Heterogeneous epigenetic regulation of TIMP3 in prostate cancer

Epigenetics

Volumn 7, Issue 11, 2012, Pages 1279-1289

  Shinojima, Toshiaki ^a   Yu, Qiang ^b   Huang, Sharon K ^a   Li, Michelle ^a   Mizuno, Ryuichi ^a   Liu, Edison T ^b,c   Hoon, Dave S B ^a   Lessard, Laurent ^a  

^a SAINT JOHN'S HEALTH CENTER   (United States)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

^c JACKSON LABORATORY   (United States)

Author keywords

DNA methylation; Epigenetic drugs; Histone modifications; Prostate cancer; TIMP3

Indexed keywords

EID: 84868348205     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.22333     Document Type: Article

References (42)

1. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284:67-8. PMID:6243750; http://dx.doi.org/10.1038/284067a0.
2. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008; 29:258-289. PMID:18762209; http://dx.doi.org/10.1016/j.mam.2008.08.001.
3. Cruz-Munoz W, Khokha R. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci 2008; 45:291-338. PMID:18568853; http://dx.doi.org/10.1080/10408360801973244.
4. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinaseindependent biological activities. Sci Signal 2008; 1:re6. PMID:18612141; http://dx.doi.org/10.1126/scisignal.127re6.
5. Deng X, Bhagat S, Dong Z, Mullins C, Chinni SR, Cher M. Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel. Eur J Cancer 2006; 42:3267-3273. PMID:16950615; http://dx.doi.org/10.1016/j.ejca.2006.07.003.
6. Zhang L, Zhao L, Zhao D, Lin G, Guo B, Li Y, et al. Inhibition of tumor growth and induction of apoptosis in prostate cancer cell lines by overexpression of tissue inhibitor of matrix metalloproteinase-3. Cancer Gene Ther 2010; 17:171-179. PMID:19798124; http://dx.doi.org/10.1038/cgt.2009.59.
7. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999; 59:798-802; PMID:10029065.
8. Yamanaka M, Watanabe M, Yamada Y, Takagi A, Murata T, Takahashi H, et al. Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 2003; 106:382-387. PMID:12845678; http://dx.doi.org/10.1002/ijc.11227.
9. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64:1975-1986. PMID:15026333; http://dx.doi.org/10.1158/0008-5472.CAN-03-3972.
10. Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10:8472-8478. PMID:15623627; http://dx.doi.org/10.1158/1078-0432.CCR-04-0894.
11. Kwabi-Addo B, Wang S, Chung W, Jelinek J, Patierno SR, Wang BD, et al. Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res 2010; 16:3539-3547. PMID:20606036; http://dx.doi.org/10.1158/1078-0432.CCR-09-3342.
12. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21:103-107. PMID:9916800; http://dx.doi.org/10.1038/5047.
13. Shin YJ, Kim JH. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. PLoS One 2012; 7:e30393. PMID:22272343; http://dx.doi.org/10.1371/journal.pone.0030393.
14. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004; 101:811-816. PMID:14711987; http://dx.doi.org/10.1073/pnas.0304146101.
15. Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003; 63:3877-3882. PMID:12873976.
16. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang- Rodriguez J, Moskaluk CA, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001; 61:5974-5978. PMID:11507037.
17. Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB, et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006; 66:4011-4019. PMID:16618720; http://dx.doi.org/10.1158/0008-5472.CAN-05-3055.
18. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8:393-406. PMID:16286247; http://dx.doi.org/10.1016/j.ccr.2005.10.001.
19. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22:2790-279. PMID:15254046; http://dx.doi.org/10.1200/JCO.2004.05.158.
20. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39:41-51. PMID:17173048; http://dx.doi.org/10.1038/ng1935.
21. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R, et al. Gene expression analysis of prostate cancers. Mol Carcinog 2002; 33:25-35. PMID:11807955; http://dx.doi.org/10.1002/mc.10018.
22. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1:203-209. PMID:12086878; http://dx.doi.org/10.1016/S1535-6108(02)00030-2.
23. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by humanpapillomavirus 18. Carcinogenesis 1997; 18:1215-1523. PMID:9214605; http://dx.doi.org/10.1093/carcin/18.6.1215.
24. Jiang X, Tan J, Li J, Kivimäe S, Yang X, Zhuang L, et al. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 2008; 13:529-541. PMID:18538736; http://dx.doi.org/10.1016/j.ccr.2008.04.019.
25. Sun F, Chan E, Wu Z, Yang X, Marquez VE, Yu Q. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Mol Cancer Ther 2009; 8:3191-202. PMID:19934278; http://dx.doi.org/10.1158/1535-7163.MCT-09-0479.
26. Yoshimura T, Nagahara M, Kuo C, Turner RR, Soon-Shiong P, Hoon DS. Lymphovascular invasion of colorectal cancer is correlated to SPARC expression in the tumor stromal microenvironment. Epigenetics 2011; 6:1001-1011. PMID:21725199; http://dx.doi.org/10.4161/epi.6.8.16063.
27. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S, et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 2011; 21:1028-1041. PMID:21724842; http://dx.doi.org/10.1101/gr.119347.110.
28. Stamey TA, Warrington JA, Caldwell MC, Chen Z, Fan Z, Mahadevappa M, et al. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol 2001; 166:2171-2177. PMID:11696729; http://dx.doi.org/10.1016/S0022-5347(05)65528-0.
29. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007; 130:77-88. PMID:17632057; http://dx.doi.org/10.1016/j.cell.2007.05.042.
30. Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 2011; 60:753-766. PMID:21719191; http://dx.doi.org/10.1016/j.eururo.2011.06.035.
31. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004; 59:177-189. PMID:15042618; http://dx.doi.org/10.1002/pros.20022.
32. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006; 66:11341-11347. PMID:17145880; http://dx.doi.org/10.1158/0008-5472.CAN-06-1570.
33. Jung-Hynes B, Nihal M, Zhong W, Ahmad N. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem 2009; 284:3823-3832. PMID:19075016; http://dx.doi.org/10.1074/jbc.M807869200.
34. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 2009; 9:773-784. PMID:19851313; http://dx.doi.org/10.1038/nrc2736.
35. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007; 39:237-242. PMID:17211412; http://dx.doi.org/10.1038/ng1972.
36. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007; 39:157-158. PMID:17200673; http://dx.doi.org/10.1038/ng1941.
37. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007; 39:232-236. PMID:17200670; http://dx.doi.org/10.1038/ng1950.
38. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008; 40:741-750. PMID:18488029; http://dx.doi.org/10.1038/ng.159.
39. Gal-Yam EN, Egger G, Iniguez L, Holster H, Einarsson S, Zhang X, et al. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A 2008; 105:12979-12984. PMID:18753622; http://dx.doi.org/10.1073/pnas.0806437105.
40. Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, et al. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res 2010; 70:5953-5962. PMID:20587525; http://dx.doi.org/10.1158/0008-5472.CAN-10-0617.
41. Walton TJ, Li G, Seth R, McArdle SE, Bishop MC, Rees RC. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate 2008; 68:210-222. PMID:18092350; http://dx.doi.org/10.1002/pros.20673.
42. Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TL, et al. MiR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 2010; 127:1363-1372. PMID:20073067; http://dx.doi.org/10.1002/ijc.25162.